RNASET2 - An autoantigen in anaplastic large cell lymphoma identified by protein array analysis

Journal of Proteomics

Volumn 75, Issue 17, 2012, Pages 5279-5292

  Patel, Suketu ^a   Chen, Hong ^b   Monti, Laura ^c   Gould, Edith ^b   Haralambieva, Eugenia ^d   Schmid, Jasmin ^b   Toomey, David ^b   Woessmann, Wilhelm ^e   Roncador, Giovanna ^f   Hatton, Chris S R ^g   Liggins, Amanda P ^a   Taramelli, Roberto ^c   Banham, Alison H ^a   Acquati, Francesco ^c   Murphy, Derek ^b,h   Pulford, Karen ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c UNIVERSITY OF INSUBRIA   (Italy)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e JUSTUS LIEBIG UNIVERSITY   (Germany)

^f Centro Nacional de Investigaciones Oncológicas   (Spain)

^g JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^h DUBLIN INSTITUTE OF TECHNOLOGY   (Ireland)

Author keywords

ALCL; Autoantibodies; Lymphoma; Protein arrays; RNASET2

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; AUTOANTIBODY; AUTOANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; LIPID PHOSPHATE PHOSPHATASE RELATED PROTEIN 3; MESSENGER RNA; PHOSPHATASE; RIBONUCLEASE; RIBONUCLEASE T2; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; LEUKOCYTE; NUCLEOTIDE SEQUENCE; PANCREAS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MICROARRAY; SPLEEN;

ANIMALS; AUTOANTIGENS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; FEMALE; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MALE; MICE; MIDDLE AGED; PROTEIN ARRAY ANALYSIS; RIBONUCLEASES; TISSUE DISTRIBUTION; TUMOR SUPPRESSOR PROTEINS; VALIDATION STUDIES AS TOPIC;

EID: 84865539913     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.06.009     Document Type: Article

References (69)

1. Soussi T. p53 antibodies in the sera of patients with various tyes of cancer: a review. Cancer Res 2000, 60:1777-1788.
2. Wang X., Yu J., Sreekumar A., Varambally S., Shen R., Giacherio D., et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005, 353:1224-1235.
3. Pallasch C.P., Struss A.K., Munia A., Konig J., Steudel W.I., Fischer U., et al. Autoantibodies against GLEA2 and PHF3 in glioblastoma:tumour-associated autoantibodies correlated with prolonged survival. Int J Cancer 2005, 117:456-459.
4. Kijanka G., Hector S., Kay E.W., Murray F., Cummins R., Murphy D., et al. Human IgG antibody profiles differentiate between symptomatic patients with and without colorectal cancer. Gut 2010, 59:69-78.
5. Bradford T.J., Wang X., Chinnaiyan A.M. Cancer immunomics: using autoantibody signatures in the early detection of prostate cancer. Urol Oncol 2006, 24:237-242.
6. Casiano C.A., Mediavilla-Varela M., Tan E.M. Tumor-associated antigen arrays for the serological diagnosis of cancer. Mol Cell Proteomics 2006, 5:1745-1759.
7. Jager E., Gnjatic S., Nagata Y., Stockert E., Jager D., Karbach J., et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A 2000, 97:12198-12203.
8. Caballero O.L., Chen Y.T. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009, 100:2014-2021.
9. Davies D.H., Liang X., Hernandez J.E., Randall A., Hirst S., Mu Y., et al. Profiling the humoral response to infection using proteome microarrays: high through-put vaccine and diagnostic antigen discovery. Proc Natl Acad Sci USA 2005, 102:547-552.
10. Bussow K., Nordhoff E., Lübbert C., Lehrach H., Walter G. A human cDNA library for high-throughput protein expression screening. Genomics 2000, 65:1-8.
11. Bussow K., Konthur Z., Lueking A., Lehrach H., Walter G. Protein array technology. Potential use in medical diagnostics. Am J Pharmacogenomics 2001, 1:37-43.
12. Murphy D., Cahill D.J. Protein Arrays. Encyclopedia of Genetics, Genomics, Proteomics and Bioinformatics 2005, 5.
13. Kijanka G., Murphy D. Protein arrays as tools for serum autoantibody marker discovery in cancer. J Proteomics 2009, 72:936-944.
14. Horn S., Lueking A., Murphy D., Staudt A., Gutjahr C., Schulte K., et al. Profiling humoral autoimmune repertoire of dilated cardiomyopathy (DCM) patients and development of a disease-associated protein chip. Proteomics 2006, 6:605-613.
15. Balboni I., Chan S.M., Kattah M., Tenenbaum J.D., Butte A.J., Utz P.J. Multiplexed protein array platforms for analysis of autoimmune diseases. Annu Rev Immunol 2006, 24:391-418.
16. Burkhardt B., Zimmermann M., Oschlies I., Niggli F., Mann G., Parwaresch R., et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol 2005, 131:39-49.
17. Savage K.J., Harris N.L., Vose J.M., Ullrich F., Jaffe E.S., Connors J.M., et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008, 111:5496-5504.
18. Delsol G., Jaffe E.S., Falini B., Gascoyne R.D., Muller-Hermelink H.K., Stein H., et al. Anaplastic large cell lymphoma (ALCL), ALK-positive. WHO Classification of tumours of Haematopoietic and lymphoid tissues 2008, 312-316. International Agency for Research on Cancer, Lyon. S.H. Swerdlow (Ed.).
19. Pulford K., Falini B., Banham A.H., Codrington D., Roberton H., Hatton C., et al. Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. Blood 2000, 96:1605-1607.
20. Ait-Tahar K., Cerundolo V., Banham A.H., Hatton C., Blanchard T., Kusec R., et al. B and CTL responses to the ALK protein in patients with ALK-positive ALCL. Int J Cancer 2006, 118:688-695.
21. Woessmann W., Peters C., Lenhard M., Burkhardt B., Sykora K.W., Dilloo D., et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents-a Berlin-Frankfurt-Munster group report. Br J Haematol 2006, 133:176-182.
22. Ait-Tahar K., Damm-Welk C., Burkhardt B., Zimmermann M., Klapper W., Reiter A., et al. Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. Blood 2010, 115:3314-3319.
23. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
24. Younes A., Bartlett N.L., Leonard J.P., Kennedy D.A., Lynch C.M., Sievers E.L., et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010, 363:1812-1821.
25. Mason D.Y., Campo E., Harris N.L., Kinney M.C., Delsol G., Jaffe E.S., et al. Anaplastic large cell lymphoma (ALCL), ALK-negative. WHO Classification of tumours of Haematopoietic and lymphoid tissues 2008, 317-319. International Agency for Research on Cancer, Lyon. S.H. Swerdlow (Ed.).
26. Schmitz N., Trumper L., Ziepert M., Nickelsen M., Ho A.D., Metzner B., et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010, 116:3418-3425.
27. Acquati F., Morelli C., Cinquetti R., Bianchi M.G., Porrini D., Varesco L., et al. Cloning and characterization of a senescence inducing and class II tumor suppressor gene in ovarian carcinoma at chromosome region 6q27. Oncogene 2001, 20:980-988.
28. Campomenosi P., Cinquetti R., Tallarita E., Lindqvist C., Raimondi I., Grassi P., et al. Comparison of the baculovirus-insect cell and Pichia pastoris heterologous systems for the expression of the human tumor suppressor protein RNASET2. Biotechnol Appl Biochem 2011, 58:39-49.
29. Pulford K., Banham A.H., Lyne L., Jones M., Ippolito G.C., Liu H., et al. The BCL11AXL transcription factor: its distribution in normal and malignant tissues and use as a marker for plasmacytoid dendritic cells. Leukemia 2006, 20:1439-1441.
30. Dervan E.W., Chen H., Ho S.L., Brummel N., Schmid J., Toomey D., et al. Protein macroarray profiling of serum autoantibodies in pseudoexfoliation glaucoma. Invest Ophthalmol Vis Sci 2010, 51:2968-2975.
31. Trinei M., Lanfrancone L., Campo E., Pulford K., Mason D.Y., Pelicci P.G., et al. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. Cancer Res 2000, 60:793-798.
32. Touriol C., Greenland C., Lamant L., Pulford K., Bernard F., Rousset T., et al. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood 2000, 95:3204-3207.
33. He Y., Wu Y., Mou Z., Li W., Zou L., Fu T., et al. Proteomics-based identification of HSP60 as a tumor-associated antigen in colorectal cancer. Proteomics Clin Appl 2007, 1:336-342.
34. Sahin U., Tureci O., Schmitt H., Cochlovius B., Johannes T., Schmits R., et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 1995, 92:11810-11813.
35. Tureci O., Sahin U., Pfreundschuh M. Serological analysis of human tumor antigens: molecular definition and implications. Mol Med Today 1997, 3:342-349.
36. Liggins A.P., Guinn B.A., Hatton C.S., Pulford K., Banham A.H. Serologic detection of diffuse large B-cell lymphoma-associated antigens. Int J Cancer 2004, 110:934.
37. Lueking A., Huber O., Wirths C., Schulte K., Stieler K.M., Blume-Peytavi U., et al. Profiling of alopecia areata autoantigens based on protein microarray technology. Mol Cell Proteomics 2005, 4:1382-1390.
38. Kijanka G., Barry R., Chen H., Gould E., Seidlits S.K., Schmid J., et al. Defining the molecular target of an antibody derived from nuclear extract of Jurkat cells using protein arrays. Anal Biochem 2009, 395:119-124.
39. Ait-Tahar K., Damm-Welk C., Burkhardt B., Zimmermann M., Klapper W., Reiter A., et al. Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. Blood 2010, 115:3314-3319.
40. Trubia M., Sessa L., Taramelli R. Mammalian Rh/T2/S-glycoprotein ribonuclease family genes: cloning of a human member located in a region of chromosome 6 (6q27) frequently deleted in human malignancies. Genomics 1997, 42:342-344.
41. Acquati F., Nucci C., Bianchi M.G., Gorletta T., Taramelli R. Molecular cloning, tissue distribution, and chromosomal localization of the human homolog of the R2/Th/Stylar ribonuclease gene family. Methods Mol Biol 2001, 160:87-101.
42. Acquati F., Possati L., Ferrante L., Campomenosi P., Talevi S., Bardelli S., et al. Tumor and metastasis suppression by the human RNASET2 gene. Int J Oncol 2005, 26:1159-1168.
43. Campomenosi P., Salis S., Lindqvist C., Mariani D., Nordstrom T., Acquati F., et al. Characterization of RNASET2, the first human member of the Rh/T2/S family of glycoproteins. Arch Biochem Biophys 2006, 449:17-26.
44. Irie M., Ohgi K. Ribonuclease T2. Methods Enzymol 2001, 341:42-55.
45. Deshpande R.A., Shankar V. Ribonucleases from T2 family. Crit Rev Microbiol 2002, 28:79-122.
46. Luhtala N., Parker R. T2 Family ribonucleases: ancient enzymes with diverse roles. Trends Biochem Sci 2010, 35:253-259.
47. Monti L., Rodolfo M., Lo Russo G., Noonan D., Acquati F., Taramelli R. RNASET2 as a tumor antagonizing gene in a melanoma cancer model. Oncol Res 2008, 17:69-74.
48. Liu J., Zhawar V.K., Kaur G., Kaur G.P., Deriel J.K., Kandpal R.P., et al. Chromosome 6 encoded RNaseT2 protein is a cell growth regulator. J Cell Mol Med 2009, 14:1146-1155.
49. Acquati F., Bertilaccio S., Grimaldi A., Monti L., Cinquetti R., Bonetti P., et al. Microenvironmental control of malignancy exerted by RNASET2, a widely conserved extracellular RNase. Proc Natl Acad Sci U S A 2011, 108:1104-1109.
50. Liu J., Zhawar V.K., Kaur G., Kaur G.P., Deriel J.K., Kandpal R.P., et al. Chromosome 6 encoded RNaseT2 protein is a cell growth regulator. J Cell Mol Med 2010, 14:1146-1155.
51. Haud N., Kara F., Diekmann S., Henneke M., Willer J.R., Hillwig M.S., et al. rnaset2 mutant zebrafish model familial cystic leukoencephalopathy and reveal a role for RNase T2 in degrading ribosomal RNA. Proc Natl Acad Sci U S A 2011, 108:1099-1103.
52. Adikesavan A.K., Unni E., Jaiswal A.K. Overlapping signal sequences control nuclear localization and endoplasmic reticulum retention of GRP58. Biochem Biophys Res Commun 2008, 377:407-412.
53. Liu Y., Emilion G., Mungall A.J., Dunham I., Beck S., Le Meuth-Metzinger V.G., et al. Physical and transcript map of the region between D6S264 and D6S149 on chromosome 6q27, the minimal region of allele loss in sporadic epithelial ovarian cancer. Oncogene 2002, 21:387-399.
54. Kim T.Y., Zhong S., Fields C.R., Kim J.H., Robertson K.D. Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. Cancer Res 2006, 66:7490-7501.
55. Hayashi Y., Raimondi S.C., Look A.T., Behm F.G., Kitchingman G.R., Pui C.H., et al. Abnormalities of the long arm of chromosome 6 in childhood acute lymphoblastic leukemia. Blood 1990, 76:1626-1630.
56. Gaidano G., Hauptschein R.S., Parsa N.Z., Offit K., Rao P.H., Lenoir G., et al. Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma. Blood 1992, 80:1781-1787.
57. Offit K., Parsa N.Z., Gaidano G., Filippa D.A., Louie D., Pan D., et al. 6q deletions define distinct clinico-pathologic subsets of non-Hodgkin's lymphoma. Blood 1993, 82:2157-2162.
58. Menasce L.P., Orphanos V., Santibanez-Koref M., Boyle J.M., Harrison C.J. Common region of deletion on the long arm of chromosome 6 in non-Hodgkin's lymphoma and acute lymphoblastic leukaemia. Genes Chromosom Cancer 1994, 10:286-288.
59. Steinemann D., Gesk S., Zhang Y., Harder L., Pilarsky C., Hinzmann B., et al. Identification of candidate tumor-suppressor genes in 6q27 by combined deletion mapping and electronic expression profiling in lymphoid neoplasms. Genes Chromosom Cancer 2003, 37:421-426.
60. Smirnoff P., Roiz L., Angelkovitch B., Schwartz B., Shoseyov O. A recombinant human RNASET2 glycoprotein with antitumorigenic and antiangiogenic characteristics: expression, purification, and characterization. Cancer 2006, 107:2760-2769.
61. Klein G., Imreh S., Zabarovsky E.R. Why do we not all die of cancer at an early age?. Adv Cancer Res 2007, 98:1-16.
62. Klein G. Toward a genetics of cancer resistance. Proc Natl Acad Sci U S A 2009, 106:859-863.
63. Dave S.S., Wright G., Tan B., Rosenwald A., Gascoyne R.D., Chan W.C., et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004, 351:2159-2169.
64. Lenz G., Wright G., Dave S.S., Xiao W., Powell J., Zhao H., et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008, 359:2313-2323.
65. Casey G., Lopez M.E., Ramos J.C., Plummer S.J., Arboleda M.J., Shaughnessy M., et al. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 1996, 13:1971-1981.
66. Ward R.L., Hawkins N.J., Coomber D., Disis M.L. Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer. Hum Immunol 1999, 60:510-515.
67. Cho Y.S., Park Y.G., Lee Y.N., Kim M.K., Bates S., Tan L., et al. Extracellular protein kinase A as a cancer biomarker: its expression by tumor cells and reversal by a myristate-lacking Calpha and RIIbeta subunit overexpression. Proc Natl Acad Sci U S A 2000, 97:835-840.
68. Quan C., Ren Y.Q., Xiang L.H., Sun L.D., Xu A.E., Gao X.H., et al. Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC. Nat Genet 2010, 42:614-618.
69. Chu X., Pan C.M., Zhao S.X., Liang J., Gao G.Q., Zhang X.M., et al. A genome-wide association study identifies two new risk loci for Graves' disease. Nat Genet 2011, 43:897-901.